ArticleFrontiers in immunology2022
Comprehensive
Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.
- Epithelial membrane protein 1 in human cancer: a potential diagnostic biomarker and therapeutic target.Biomarkers in medicine · 2024Pooled it
- Integrative multi-omics analysis reveals an 11-gene malignant-myeloid interaction signature and identifies TPST1 as a potential regulator of immunosuppressive microenvironment in glioma.Discover oncology · 2026Article
- Identification and Validation of a Four-Gene Signature as a Novel Potential Diagnostic Biomarker Panel for Endometriosis: Causal and Mechanistic Insights from Mendelian Randomization and Bioinformatics.International journal of women's health · 2026Article
- FGFR Inhibitors in Urothelial Cancer: From Scientific Rationale to Clinical Development.Journal of Korean medical science · 2024Review
- Article
- Establishment of a SUMO pathway related gene signature for predicting prognosis, chemotherapy response and investigating the role of EGR2 in bladder cancer.Journal of Cancer · 2024Article
- Identification of a Novel Mesenchymal Stem Cell-Related Signature for Predicting the Prognosis and Therapeutic Responses of Bladder Cancer.Stem cells international · 2024Article
- CERCAM is a prognostic biomarker associated with immune infiltration of macrophage M2 polarization in head and neck squamous carcinoma.BMC oral health · 2023Article
- An estrogen response-related signature predicts response to immunotherapy in melanoma.Frontiers in immunology · 2023Article
- Cancer-associated fibroblast-related gene signatures predict survival and drug response in patients with colorectal cancer.Frontiers in genetics · 2022Article
- OSBPL10-CNBP axis mediates hypoxia-induced pancreatic cancer development.BioFactors (Oxford, England)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Bladder cancer (BC) threatens the health of human beings worldwide because of its high recurrence rate and mortality. As an actionable biomarker, fibroblast growth factor receptor 3 ( Materials and Methods: Genomic alteration profile, gene expression data, and related clinical information of BC patients were downloaded from The Cancer Genomics database (TCGA), as a training cohort. Subsequently, the Weighted Gene Co-expression Network Analysis (WGCNA) was conducted to identify the hub modules correlated with Results: There were a total of eleven genes ( Conclusion: The novel established FARG signature based on a comprehensive
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.